AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
18 Setembro 2023 - 5:15PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company focused on delivering innovative immunology therapeutics,
today announced it has appointed John Orwin chairman of the
AnaptysBio Board of Directors.
“We are excited to welcome John to Anaptys’ Board of Directors
as chairman. With more than 25 years of diverse experience across
the biopharmaceutical landscape, John brings a track record of
substantial accomplishment across our sector as a biotech CEO and
Board member. We welcome John’s guidance and expertise in
later-stage drug development, commercial planning and overall
corporate strategy as we focus on broadly developing our
differentiated immune cell modulators, including our two checkpoint
agonists, in autoimmune and inflammatory diseases,” said Daniel
Faga, president and chief executive officer of AnaptysBio. “We
thank Jamie for his many years of service to the Board and his
partnership over the past year as we successfully refocused our
strategy on diseases with clear biology supporting immune cell
modulation, high unmet need and large commercial potential.”
Currently, Mr. Orwin serves on the Board of Directors of Seagen,
Inc., Travere Therapeutics and Cargo Therapeutics. He previously
served on the Board of Directors of Array BioPharma, Inc. Mr. Orwin
also currently serves as president and CEO of Atreca, Inc., a
clinical-stage biotechnology company, and previously was the CEO of
Relypsa, until its acquisition by Galenica, and CEO of Affymax. In
building successful businesses and commercializing a range of
blockbuster products, he has held leadership roles in marketing,
sales and operations for Genentech, Johnson & Johnson, Alza
Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer
and Schering-Plough Corporation. Mr. Orwin holds a master’s degree
in business administration from New York University and a
bachelor’s degree from Rutgers, The State University of New
Jersey.
“It is an incredibly exciting time at Anaptys as they
advance their portfolio of novel, best-in-class immune cell
modulators to treat diseases including rheumatoid arthritis and
atopic dermatitis,” said Mr. Orwin. “Anaptys is advancing the
field of immunology and inflammation with a high level of
executional excellence, expertise and commitment. I’m honored to
work collaboratively with this Board and leadership team that is
inspired by and committed to its vision to transform patient health
by delivering innovative immunology therapeutics.”
Dr. Topper has served on the AnaptysBio Board of Directors since
2007 and as chairman since 2015. During this tenure, he has
overseen the evolution of AnaptysBio from an early-stage antibody
generation platform to a clinical-stage organization. Dr. Topper
will remain in a transitionary role as an advisor to the Board
through Q1 2024.
“It has been an honor to serve on this dynamic Board of
Directors. I leave knowing that the Board and company are in good
hands as they embark on the next stage of development,” said Dr.
Topper. “I look forward to supporting John, Dan, the Board and the
rest of the team in a transitionary capacity as well as following
the Anaptys story as they focus on the development of their
immune cell modulator portfolio, an exciting new frontier in the
area of medicine.”
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company focused on
delivering innovative immunology therapeutics. It is developing
immune cell modulators, including two checkpoint agonists in
clinical-stage development, for autoimmune and inflammatory
disease: rosnilimab, its PD-1 agonist, in a planned Phase 2b trial
for the treatment of moderate-to-severe rheumatoid arthritis; and
ANB032, its BTLA agonist, currently in a Phase 2b trial for the
treatment of moderate-to-severe atopic dermatitis. Its preclinical
immune cell modulator portfolio includes ANB033, an anti-CD122
antagonist antibody for the treatment of autoimmune and
inflammatory diseases. In addition, AnaptysBio has developed two
cytokine antagonists available for out-licensing: imsidolimab, an
anti-IL-36R antagonist, in Phase 3 for the treatment of generalized
pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist
for the treatment of respiratory disorders that is Phase 2/3 ready.
AnaptysBio has also discovered multiple therapeutic antibodies
licensed to GSK in a financial collaboration for immune-oncology,
including an anti-PD-1 antagonist antibody (Jemperli
(dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab,
GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to: whether any of the Company’s products will be best in
class; and the company’s ability to find a licensing partner for
imsidolimab or etokimab and the timing of any such transaction.
Statements including words such as “plan,” “continue,” “expect,” or
“ongoing” and statements in the future tense are forward-looking
statements. These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause its results to differ
materially from those expressed or implied by such forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that may cause the company’s actual activities or
results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
related to the company’s ability to advance its product candidates,
obtain regulatory approval of and ultimately commercialize its
product candidates, the timing and results of preclinical and
clinical trials, the company’s ability to fund development
activities and achieve development goals, the company’s ability to
protect intellectual property and other risks and uncertainties
described under the heading “Risk Factors” in documents the company
files from time to time with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date of this press release, and the company undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Contact:Nick MontemaranoSenior Director,
Investor Relations and Strategic Communications AnaptysBio, Inc.
858.732.0178investors@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
AnaptysBio (NASDAQ:ANAB)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024